Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority of biosimilar infliximab (CT-P13) vs innovator infliximab in stable inflammatory disease patients
2014-002056-40Phase 4Completed
- Sponsor
- Diakonhjemmet Sykehus
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of infliximab and infliximab-dyyb in rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) and 3 more (2 arms), sponsored by Diakonhjemmet Sykehus. Primary endpoint: Disease worsening over 52 weeks. Started Jun 2014; status: completed.
02
Drugs
infliximabinfliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)spondyloarthritis (SpA)psoriatic arthritis (PsA)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2014-002056-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002056-40.